Disc Medicine, Inc. Increase (Decrease) in Other Accrued Liabilities
Disc Medicine, Inc. (IRON) reported Increase (Decrease) in Other Accrued Liabilities of -$6.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-07-30
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $2.05M, a 75.41% increase year-over-year.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$8.73M.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was $4.45M, a 90.98% increase year-over-year.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $4.95M, a 234.05% increase year-over-year.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for fiscal 2025 was $6.88M, a 309.40% increase from fiscal 2024.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for fiscal 2024 was $1.68M, a 8.59% decline from fiscal 2023.
- Disc Medicine, Inc. increase (decrease) in other accrued liabilities for fiscal 2023 was $1.84M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$6.68M 10-Q · filed 2026-07-30 | -$2.23M derived: sum of 3 quarters · filed 2026-07-30 | $2.72M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$8.73M 10-Q · filed 2026-05-05 | -$4.29M derived: sum of 2 quarters · filed 2026-05-05 | $666.00K derived: sum of 3 quarters · filed 2026-05-05 | $1.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.40M derived: sum of 2 quarters · filed 2026-02-26 | $10.57M derived: sum of 3 quarters · filed 2026-07-30 | $6.88M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.13M derived: sum of 2 quarters · filed 2026-07-30 | $2.44M 10-Q · filed 2025-11-06 | $4.76M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.52M 10-Q · filed 2026-07-30 | -$190.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$3.69M 10-Q · filed 2026-05-05 | -$1.36M derived: sum of 2 quarters · filed 2026-05-05 | $122.00K derived: sum of 3 quarters · filed 2026-05-05 | $1.08M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.81M derived: sum of 2 quarters · filed 2026-02-26 | $4.77M derived: sum of 3 quarters · filed 2026-02-26 | $1.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.44M derived: sum of 2 quarters · filed 2025-11-06 | -$647.00K 10-Q · filed 2025-11-06 | $2.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $962.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.13M 10-Q · filed 2025-08-07 | $558.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$3.09M 10-Q · filed 2025-05-07 | -$404.00K derived: sum of 2 quarters · filed 2026-02-26 | $538.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.63M derived: sum of 2 quarters · filed 2026-02-26 | $1.84M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $942.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$849.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$1.79M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |